UAE-Headquartered Crescent Enterprises Co-Leads US-Based XCath’s US$30 Million Series C Round

XCath, a Texas-based medical device company developing neuro-endovascular surgical robotics, has secured US$30 million in a Series C funding round, which brings the total capital it has raised since inception to $92 million.

The new investment was co-led by UAE-based diversified business group Crescent Enterprises (which also partly owns XCath), and Dr. Fred Moll, Chairman of XCath's board of directors.

Founded in 2017 as a spinout from the University of Texas’ Microsurgical Robotics Laboratory, XCath is building an endovascular robotic system intended for clinical use, with the new capital set to support the company’s efforts to bring its technology to market, alongside plans to carry out a clinical telerobotic mechanical thrombectomy.

The new investment in XCath follows a key clinical milestone it achieved in November last year, when the company completed a robotic-assisted procedure using its Iris system to treat patients with complex brain aneurysms. The procedures were performed by Dr. Vitor Mendes Pereira at The Panama Clinic in Panama, in collaboration with local principal investigator Dr. Anastasio Ameijeiras Sibauste, marking the second time a robotic system has been used in an intracranial neurovascular intervention.

In an interview with Inc. Arabia, Neeraj Agrawal, Executive Director of Crescent Enterprises, pointed to XCath’s progress and broader market dynamics as key factors behind the UAE-based firm’s decision to fund the American enterprise.

“Crescent Enterprises has a robust appetite for early-stage transformational businesses, and when such businesses demonstrate substantial meaningful progress and potential for market leadership, our approach is to deepen our exposure and continue supporting their research and growth,” Agrawal said. “XCath has rapidly emerged as the world’s leading robotic neurovascular company. The combination of a large market and unmet clinical need, particularly in stroke treatment, together with the profound humanitarian impact of improving access to neurovascular procedures, makes XCath a uniquely compelling investment opportunity. The company’s technical progress, clinical momentum, and growing leadership in robotic neurovascular intervention made this a natural case for Crescent Enterprises to further strengthen its investment in XCath.”

Neeraj Agrawal, Executive Director of Crescent Enterprises. Image supplied.

Agrawal also pointed out that as the burden of stroke and related conditions continues to strain healthcare systems globally, attention is turning to technologies—like that of XCath’s—that can expand access to timely intervention. “Stroke is widely regarded as one of the most compelling cases for telerobotics and remote intervention due to geographical diversity and need for timely intervention,” he explained. “Today, significant logistical and economically viable resource barriers mean that advanced procedures such as thrombectomy remain severely underutilized across the world. XCath’s technology directly addresses this challenge by enabling highly precise, remotely deliverable interventions for acute neurovascular procedures. By extending specialist expertise beyond major medical centers, XCath has the potential to dramatically expand global access to life-saving stroke treatment. Beyond stroke, the neurovascular field is evolving rapidly, with emerging technologies in areas such as complex aneurysm treatment and brain-computer interfaces. XCath’s sub-millimetric precision robotic platform will help support the safe and effective delivery of these next-generation neurovascular therapies.”

According to Agrawal, the implications of robotics extend beyond neurovascular care, particularly in improving precision and widening access to specialized procedures across healthcare systems. “There are several areas where robotics can have a profound impact on patient outcomes,” he said. “First, robotics can help democratize surgical precision. Today, the highest levels of procedural expertise are concentrated among a relatively small number of physicians. Robotic systems, including platforms like XCath’s, can help extend that level of precision and control to a much broader physician population. This applies to all endovascular procedures and not only neuro vascular ones. Second, robotics enhances procedural control through capabilities such as motion scaling and improved stability, allowing physicians to perform delicate interventions with greater accuracy and consistency. Third, robotics enables the possibility of remote procedures, which can dramatically expand access to specialized care. Platforms like XCath’s robotic system demonstrate how robotics can bridge geographic gaps in expertise. Finally, the integration of artificial intelligence (AI) will further enhance these systems. In the near term, AI can provide guidance, decision support, and safety guardrails to augment physician decision-making, with more autonomous elements potentially emerging over time.”

For other founders navigating similarly complex sectors, Agrawal framed XCath’s journey as illustrative of a broader set of entrepreneurial fundamentals. “The first principle is the same as in any technology venture: ensure that the technology is solving a real market need rather than searching for a need,” Agrawal noted. “In healthcare technology, founders must also understand the broader ecosystem. Regulation represents a significantly higher threshold than in many other industries, and this has cascading effects throughout the company’s journey. Development timelines are longer, clinical validation is essential, and reaching the market often takes more time and capital than initially expected. In surgical robotics specifically, the complexity is even greater because every component of the system must work seamlessly together. Companies like XCath illustrate how building an integrated robotic platform requires significant capital, regulatory discipline, and long-term commitment.”

However, Agrawal highlighted that the scale of the challenge is precisely what underpins the opportunity in this domain. “The reward for navigating that journey successfully is substantial,” he noted. “Businesses in this space have the opportunity to fundamentally change how healthcare is delivered, and improve outcomes for patients around the world.”